Dr Soler. A new treatment strategy for obesity. Credit: HCB
Swallowable balloon and GLP-1 medication: a new combination that could achieve more than 20% weight loss
The Obesity Unit at HCB Hospitales has introduced a new therapeutic strategy combining the Allurion swallowable balloon with GLP-1 receptor agonist medications, such as semaglutide or tirzepatide. The latest clinical evidence shows that this combination could help selected patients achieve weight loss of more than 20% of their body weight, always under medical supervision and as part of a comprehensive treatment programme.
The approach to obesity has moved away from single treatments towards a much more personalised model of care. Today, specialists can combine different therapeutic tools according to the individual characteristics and needs of each patient, helping to improve results and support healthier, more sustainable long-term weight loss.
“Every patient has different needs, and our aim is to design the most appropriate strategy to achieve effective, safe and sustainable weight loss over time,” explains Dr Álvaro Soler, bariatric surgeon at the HCB Hospitales Obesity Unit.
A treatment combining two different mechanisms
| Treatment |
How it helps |
| Swallowable balloon |
Increases feelings of fullness during the first few months. |
| GLP-1 medication |
Helps control appetite and maintain weight loss. |
Evidence supports the combination
The first clinical studies to evaluate this combined approach have shown particularly promising results. In a series of patients treated with the Allurion balloon and semaglutide, average weight loss reached 20.3% after eight months of follow-up.
A subsequent clinical series combining the balloon with tirzepatide recorded an average weight loss of 23% after one year of treatment. The results also showed improved preservation of muscle mass and high levels of treatment adherence, important factors when supporting patients throughout their weight-loss journey.
Who is it suitable for?
Not every patient requires or is suitable for this combined treatment. Following a comprehensive medical assessment, the Obesity Unit team determines the most appropriate strategy based on factors including body mass index, associated health conditions, previous treatments and individual weight-loss goals.
This personalised assessment allows specialists to select the most suitable treatment options and carefully monitor each patient’s progress.
A comprehensive treatment, not a quick fix
Specialists emphasise that no treatment can achieve lasting results without changes to lifestyle habits. Healthy eating, regular physical activity, ongoing medical monitoring and nutritional support remain the foundations of successful obesity treatment and sustainable weight management.
The introduction of this combined strategy further reinforces HCB Hospitales’ commitment to personalised treatments based on scientific evidence. By incorporating new therapeutic options into its comprehensive approach to obesity care, the hospital group continues to offer patients additional alternatives for managing a complex condition and achieving healthier, sustainable weight loss.
For more information visit: www.hcbhospitales.com
